L NPM1-m and 96% of 1L KMT2A-r AML patients alive as of data cutoff with median follow-up of 31 and 19 weeks, respectively – – Promising clinical activity in R/R NPM1-m and KMT2A-r AML with ven/aza, ...
Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant ...
Verition Fund Management LLC acquired a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the 3rd ...
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
The all-oral combination of revumenib, venetoclax, and ASTX727 demonstrated efficacy in relapsed/refractory AML.
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd ...
The disgraced film producer was diagnosed with leukaemia in November. Now his lawyer has confirmed that the 72-year-old was rushed to hospital after an "alarming blood test result". His lawyer, Imran ...
Genmab A/S (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell ...